At Nemera, we are your holistic partner to develop and manufacture patient-centric inhalersDiscover More
A breath of expertise
From the concept idea to large scale manufacturing, we’re the utmost holistic partner to develop your inhalers. We help our customers succeed in the sprint to market with their formulations targeting the inhalation treatments.
We also are an active contributor to the scientific community and we strive to consider in our research evolving trends in inhalation and in patient needs, as well as increasing interest to digital and sustainability related factors.
Integrated services from device selection to GMP manufacturing
We have developed end-to-end services and expertise in inhaler development, device consulting, clinical trial support and contract manufacturing to complement our diverse portfolio of products to help you through every step of the journey.
We are an active contributor to the scientific community and we strive to consider in our researchs evolving trends in inhalation and in patient needs, as well as increasing interest in digital and sustainability-related factors.
Thanks to our high-end laboratory facilities we can test inhaler performances, as well as test methods development for our customers’ needs.
Nemera designs and develops 2 types of inhalers, Pressurized Metered Dose Inhalers and Dry Powder Inhalers, to treat the following diseases:
- Asthma is a chronic inflammatory disease is a chronic disease of the air passages of the lungs which causes recurring symptoms, such as reversible airflow obstruction, episodes of wheezing, coughing, chest tightness, and shortness of breath. It was estimated that more than 339 million people had Asthma globally in 2016. There is no cure for asthma, but symptoms can be prevented by using of inhaled corticosteroids.
- COPD (Chronic obstructive pulmonary disease) is a type of obstructive lung disease characterized by long-term breathing problems and poor airflow. The main symptoms include shortness of breath and cough with sputum production. Globally, it is estimated that 3.17 million deaths were caused by the disease in 2015 (that is, 5% of all deaths globally in that year). COPD treatments include smoking cessation, vaccinations, respiratory rehabilitation, and often inhaled bronchodilators and steroids.
Inhalers are drug delivery devices used to administer the drug into the lungs through patient’s breathing. This allows medicines for lung treatments to be delivered directly to the diseased lungs allowing a rapid effect as well as a reduction in the side effects of oral or injectable medications.
A Dry Powder Inhaler (DPI) is a type of inhaler commonly used to deliver powder formulations into the lungs.
A DPI can be preloaded with the medication(s) or loaded by a patient with capsules as the dose-holding system, prior to use. DPIs are breath-activated as the medication is released only when you take a deep, fast breath in through the inhaler. This is different than a metered dose inhaler that pushes medication into the lungs.
In DPIs, a patient’s breathing capacity is critical in generating the desired therapeutic outcome as the dispersed powder needs to be broken into particles of the right size and be deposited appropriately into the lungs.
A Pressurized Metered-Dose Inhaler (pMDI) is a device used to deliver medication into the lungs. It is composed of a pressurized canister of medication that fits into a mouthpiece.
In most instances, a dose of medication is released into the lungs by pushing the canister into the mouthpiece.
Breath-activated pMDIs release medication automatically when the patient inhales. Most pressurized metered-dose inhalers have counters that track how many doses remain in the canister.